Fig. 7: BRD4 inhibitor impairs the growth of ER+ breast tumors enhanced by USP35 overexpression.

A ZR-75-1 cells stably expressing with vector or USP35 was injected orthotopically into the 4th mammary fat pad of the BABL/C nude female mice, which were treated with vehicle or BRD4 inhibitor (+)-JQ-1 at the indicated time points (n = 5). B The growth of the ZR-75-1 tumors in response to treatment with (+)-JQ-1 over the course of the experiment. The volumes of the tumors were recorded every 2 days, and the tumor growth curves were plotted. C The weights of mice were not different in three groups. Tumors were dissected out from the euthanized mice at the end of the experiment, photographed (D), and weighted (E) (n = 5). F Iamges depicting Hematoxylin and Eosin (H&E) staining and immunostaining for SLC7A11 and 4-HNE in ZR-75-1 tumors with the indicated treatments. Scale bar = 50 μm. G SLC7A11 and 4-HNE IHC staining intensities were quantified and scored (n = 5). Data are shown as Mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.